EnzySurge
Rosh Ha'ayin · Founded 2001
About EnzySurge
EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. The company was founded in 2001 by Professor Amihay Freeman of the University of Tel Aviv. EnzySurge's flagship DermaStream® platform, based on the proprietary Continuous Streaming Therapy™ (CST) technology, offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced bio-active therapeutic solutions to a controlled wound environment. DermaStream® is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment cycle from debridement, through regeneration to wound closure. DermaStream® was designed for use in hospitals, clinics, nursing homes and for home care. EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients by shortening healing time, preventing hospitalization and reducing treatment costs.
Company Facts
- Founded: 2001
- Legal name: EnzySurge Ltd.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.1M
- Last round: Series Unknown (Jan 2010)
- Website: enzysurge.com
- Phone: 972 3 622 7600
Social Profiles
Canonical: https://fsome.com/organization/enzysurge-8387780 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.